Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
On October 11, 2010, the Administrators of the Deferred Investment Award Plan notified the Company of an increase in share interests for specific individuals. This increase resulted from the re-investment of dividends paid to shareholders on October 7, 2010, at a price of £12.87 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Increase in ordinary share interests via dividend re-investment.
- Share Price: £12.87 per share.
- Dividend Date: October 7, 2010.
- Notification Date: October 11, 2010.
- Individuals Notified: Mr E J Gray, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, and Mr P J T Vallance.